122 related articles for article (PubMed ID: 9460339)
1. Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND).
Keating MJ; McLaughlin P; Cabanillas F
Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):21-6. PubMed ID: 9460339
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
[TBL] [Abstract][Full Text] [Related]
3. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Dimopoulos MA; Fountzilas G; Papageorgiou E; Kiamouris C; Mantzios G; Anagnostopoulos A; Nicolaides C; Economopoulos T;
Leuk Lymphoma; 2002 Jan; 43(1):111-4. PubMed ID: 11908713
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Pate O; Romaguera JE; Rodriguez MA; Redman JR; Keating M
J Clin Oncol; 1994 Mar; 12(3):575-9. PubMed ID: 8120556
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Bordonaro R; Petralia G; Restuccia N; Todaro AM; Serraino D; Giuffrida D; Cordio S; Giannitto-Giorgio C; Salice P; Ursino M; Novello G; Marletta F; Manusia M
Leuk Lymphoma; 2004 Jan; 45(1):93-100. PubMed ID: 15061203
[TBL] [Abstract][Full Text] [Related]
7. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
Nastoupil LJ; McLaughlin P; Feng L; Neelapu SS; Samaniego F; Hagemeister FB; Ayala A; Romaguera JE; Goy AH; Neal E; Wang M; Fayad L; Fanale MA; Oki Y; Westin JR; Rodriguez MA; Cabanillas F; Fowler NH
Br J Haematol; 2017 Apr; 177(2):263-270. PubMed ID: 28340281
[TBL] [Abstract][Full Text] [Related]
8. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
[TBL] [Abstract][Full Text] [Related]
10. Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Semin Oncol; 2002 Feb; 29(1 Suppl 2):48-55. PubMed ID: 11842389
[TBL] [Abstract][Full Text] [Related]
11. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis.
Shin DY; Kim SJ; Yoon DH; Park Y; Kong JH; Kim JA; Kim BS; Kim HJ; Won JH; Park SK; Kim WS
Cancer Chemother Pharmacol; 2016 Apr; 77(4):865-73. PubMed ID: 26984211
[TBL] [Abstract][Full Text] [Related]
13. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
Srokowski TP; Liebmann JE; Modiano MR; Cohen GI; Pro B; Romaguera JE; Kuepfer C; Singer JW; Fayad LE
Cancer; 2011 Nov; 117(22):5067-73. PubMed ID: 21681734
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
McLaughlin P; Hagemeister FB; Romaguera JE; Sarris AH; Pate O; Younes A; Swan F; Keating M; Cabanillas F
J Clin Oncol; 1996 Apr; 14(4):1262-8. PubMed ID: 8648382
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas.
Zinzani PL; Magagnoli M; Bendandi M; Gherlinzoni F; Orcioni GF; Cellini C; Stefoni V; Pileri SA; Tura S
Ann Oncol; 2000 Mar; 11(3):363-5. PubMed ID: 10811507
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
[TBL] [Abstract][Full Text] [Related]
18. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
[TBL] [Abstract][Full Text] [Related]
19. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Santini G; Nati S; Spriano M; Gallamini A; Pierluigi D; Congiu AM; Truini M; Rubagotti A; Chisesi T; Vimercati R; Rossi E; Sertoli MR; Mattei D; Marino G; Gobbi M
Haematologica; 2001 Mar; 86(3):282-6. PubMed ID: 11255275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
